drugset / Trial / NCT00004193
ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer
Phase 2
Terminated
25 enrolled
University of Alabama at Birmingham
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: ISIS 2503 may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have metastatic and/or locally recurrent colorectal cancer.
Timeline
- Start
- 1999-01
- Primary completion
- 2000-11
- Completion
- 2000-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ISIS 2503 | Antisense oligonucleotide | — | Intravenous |